![Agnes Rafalko](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Agnes Rafalko
Plus aucun poste en cours
Historique de carrière de Agnes Rafalko
Anciens postes connus de Agnes Rafalko
Sociétés | Poste | Début | Fin |
---|---|---|---|
Glycomine, Inc.
![]() Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Directeur Général | - | 01/04/2018 |
Fondateur | - | 01/04/2019 | |
President | - | 01/04/2019 |
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Chief Executive Officer | 1 |
Founder | 1 |
President | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Glycomine, Inc.
![]() Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
- Bourse
- Insiders
- Agnes Rafalko
- Expérience